Harisha E J, Gosavi Siddharth, Rao Amogh A, Sahana G V, Manjunath Sanath, Meghana T C
Department of General Medicine, JJM Medical College, Davanagere, Karnataka, India.
J Family Med Prim Care. 2022 Feb;11(2):758-761. doi: 10.4103/jfmpc.jfmpc_7_21. Epub 2022 Feb 16.
COVID-19 is known to cause extrapulmonary manifestations, including gastrointestinal and abnormal liver functions. Multiple mechanisms have been proposed to explain the pathobiology of liver damage: ACE2 receptor cholangiocytes mediated systemic inflammation, cytokine storm, hyperinflammation, and hypoxic changes. This was a cross-sectional study done in Department of General Medicine,JJM Medical College Davangere between July and September 2020 of patients falling under Category B and Category C.
The aim is to describe the clinical characteristics in patients of COVID-19 and investigate the gender difference with particular regard to liver impairment.Confirmation of COVID-19 positivity was based on RT-PCR for SARS-CoV-2 RNA. Laboratory investigations and clinical data was analyzed using SPSS Statistics 27.
The final study population consisted of 116 patients. On performing the Mann Whitney U test, adjusted values reveal a significant difference in ALT ( = 0.0348), total bilirubin ( = 0.0012) and direct bilirubin ( = 0.0024). The degree of hypoalbuminemia in males was significantly higher than in females ( = 0.0075). Other biochemical parameters, however, did not show significant difference amongst patients based on gender. Acute kidney injury was the most prevalent condition, present in 67.2% of the patients. Other co-morbidities were diabetes mellites, chronic liver disease, hypertension, hepatitis B and C, and hypothyroidism.
Ultrasonography of the abdomen is an essential investigation for all patients testing positive for COVID-19. Pre-existing disease may aggravate the viral hepatic injury, thereby worsening the clinical outcome. The profiles of liver toxicity of the drugs used in the treatment of COVID-19 also warrant watchful monitoring of liver function.
已知新型冠状病毒肺炎(COVID-19)可引起肺外表现,包括胃肠道和肝功能异常。已提出多种机制来解释肝损伤的病理生物学:血管紧张素转换酶2(ACE2)受体胆管细胞介导的全身炎症、细胞因子风暴、过度炎症和缺氧变化。这是一项横断面研究,于2020年7月至9月在达万盖雷JJM医学院普通内科进行,研究对象为B类和C类患者。
目的是描述COVID-19患者的临床特征,并调查肝损伤方面的性别差异。COVID-19阳性的确认基于针对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)RNA的逆转录聚合酶链反应(RT-PCR)。使用社会科学统计软件包(SPSS)Statistics 27对实验室检查和临床数据进行分析。
最终研究人群包括116名患者。进行曼-惠特尼U检验时,校正值显示谷丙转氨酶(ALT)(P = 0.0348)、总胆红素(P = 0.0012)和直接胆红素(P = 0.0024)存在显著差异。男性低白蛋白血症程度显著高于女性(P = 0.0075)。然而,其他生化参数在不同性别的患者中未显示出显著差异。急性肾损伤是最常见的情况,67.2%的患者存在该情况。其他合并症包括糖尿病、慢性肝病、高血压、乙型和丙型肝炎以及甲状腺功能减退。
腹部超声检查对于所有COVID-19检测呈阳性的患者都是一项必要的检查。既往疾病可能会加重病毒性肝损伤,从而使临床结局恶化。用于治疗COVID-19的药物的肝毒性情况也需要密切监测肝功能。